HRP20120870T1 - Protutijela protiv hepcidina i njihova upotreba - Google Patents
Protutijela protiv hepcidina i njihova upotreba Download PDFInfo
- Publication number
- HRP20120870T1 HRP20120870T1 HRP20120870AT HRP20120870T HRP20120870T1 HR P20120870 T1 HRP20120870 T1 HR P20120870T1 HR P20120870A T HRP20120870A T HR P20120870AT HR P20120870 T HRP20120870 T HR P20120870T HR P20120870 T1 HRP20120870 T1 HR P20120870T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequences
- antibody
- given
- Prior art date
Links
- 229940066919 hepcidin Drugs 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 238000003556 assay Methods 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims 3
- 102000009052 human hepcidin 25 Human genes 0.000 claims 3
- 108700022871 human hepcidin 25 Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 102400001151 Hepcidin-25 Human genes 0.000 claims 2
- 101800003310 Hepcidin-25 Proteins 0.000 claims 2
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 238000010166 immunofluorescence Methods 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 108091006976 SLC40A1 Proteins 0.000 claims 1
- 238000007818 agglutination assay Methods 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000005534 hematocrit Methods 0.000 claims 1
- 102000018511 hepcidin Human genes 0.000 claims 1
- 108060003558 hepcidin Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001995 reticulocyte Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Izolirano protutijelo, naznačeno time što se veže na ljudski hepcidin-25 s KD od 800 pM ili manje, što je određeno površinskom plazmonskom rezonancijom (SPR) na 25 °C i sadrži šest CDR, koje se bira iz skupine koju čine:
(i) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 52, 60, 62, 65, 71, odnosno 75;
(ii) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 42, 76, 62, 79, 87, odnosno 46;
(iii) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 41, 53, 31, 63, 84, odnosno 46;
(iv) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 43, 30, 31, 32, 44, odnosno 46;
(v) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 43, 53, 61, 63, 85, odnosno 46; i
(vi) LCDR1, LCDR2, LCDR3, HCDR1, HCDR2, te HCDR3, koji imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 43, 57, 61, 63, 84, odnosno 46.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što protutijelo ima KD za ljudski hepcidin-25 između 400 pM i 30 pM, što je određeno uz pomoć SPR na 25 °C.
3. Protutijelo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što protutijelo ima KD za ljudski hepcidin-25 između 200 pM i 30 pM, što je određeno uz pomoć SPR na 25 °C.
4. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što protutijelo ima IC50 između 100 nM i 50 nM u ispitivanju bioaktivnosti hepcidina-25 in vitro, gdje se u navedenom ispitivanju mjeri internaliziranje i/ili razgradnju feroportina induciranu hepcidinom.
5. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time što protutijelo ima IC50 između 100 nM i 25 nM u ispitivanju bioaktivnosti hepcidina-25 in vivo, gdje se u navedenom ispitivanju mjeri smanjivanje razina željeza u serumu inducirano s IL-6.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeno time što je protutijelo ljudsko modificirano protutijelo.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačeno time što se kostur varijabilnog područja lakog lanca bira između 02, 018 ili L12.
8. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeno time što se kostur varijabilnog područja teškog lanca bira između VH1-69, VH1-18 ili VH1-46.
9. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačeno time što sadrži varijabilno područje teškog lanca (HCVR) i varijabilno područje lakog lanca (LCVR), gdje (i) HCVR i LCVR imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 148 odnosno 126; (ii) HCVR i LCVR imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 128 odnosno 127; (iii) HCVR i LCVR imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 150 odnosno 124; ili (iv) HCVR i LCVR imaju aminokiselinske sljedove kao što su dani u SEQ ID NO: 151 odnosno 125.
10. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačeno time što sadrži teški lanac i laki lanac, koji imaju (i) aminokiselinske sljedove kao što su dani u SEQ ID NO: 6 odnosno 14; (ii) aminokiselinske sljedove kao što su dani u SEQ ID NO: 7 odnosno 15; (iii) aminokiselinske sljedove kao što su dani u SEQ ID NO: 9 odnosno 17; ili (iv) aminokiselinske sljedove kao što su dani u SEQ ID NO: 8 odnosno 16.
11. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačeno time što sadrži dva polipeptida teškog lanca i dva polipeptida lakog lanca, te što svaki od polipeptida teškog lanca ima aminokiselinski slijed kao što je dan u SEQ ID NO: 8, a svaki od polipeptida lakog lanca ima aminokiselinski slijed kao što je dan u SEQ ID NO: 16.
12. Polinukleotid, naznačen time što sadrži nukleotidni slijed koji kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-11.
13. Polinukleotid u skladu s patentnim zahtjevom 12, naznačen time što sadrži nukleotidni slijed koji kodira polipeptid lakog lanca, koji ima aminokiselinski slijed kao što je dan u SEQ ID NO: 14, 15, 16, ili 17.
14. Polinukleotid u skladu s patentnim zahtjevom 12, naznačen time što sadrži nukleotidni slijed kao što je dan u SEQ ID NO: 12 ili 13.
15. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-11, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
16. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačeno time što je namijenjeno upotrebi u terapiji.
17. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačeno time što je namijenjeno upotrebi u liječenju i/ili sprječavanju anemije.
18. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačeno time što je namijenjeno upotrebi u povećavanju razina željeza u serumu, broja retikulocita, broja eritrocita, hemoglobina ili hematokrita kod subjekta.
19. Imunoispitivanje, naznačeno time što se sastoji u a) dobivanju uzorka kojeg treba ispitati za zreli ljudski hepcidin; b) stavljanju u kontakt uzorka s protutijelom u skladu s bilo kojim od patentnih zahtjeva 1-11 u uvjetima pogodnim za vezanje protutijela i koji omogućuju da sav prisutan zreli ljudski hepcidin tvori kompleks s protutijelom; i c) detektiranju prisutnosti ili odsutnosti kompleksa; i/ili određivanju količine kompleksa u uzorku postupkom imunodetekcije.
20. Imunoispitivanje u skladu s patentnim zahtjevom 18, naznačeno time što je postupak imunodetekcije enzimoimunosno ispitivanje (ELISA), radioimunosno ispitivanje (RIA), imunohistokemijsko (IHC) ispitivanje, imunofluorescentno (IF) ispitivanje, ispitivanje aglutinacije, western blot ispitivanje (zapadno bugačenje), dot blot ispitivanje (točkasto bugačenje), slot blot ispitivanje ili postupak detekcije uz pomoć površinske plazmonske rezonancije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98491007P | 2007-11-02 | 2007-11-02 | |
| PCT/US2008/081493 WO2009058797A1 (en) | 2007-11-02 | 2008-10-29 | Anti-hepcidin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120870T1 true HRP20120870T1 (hr) | 2012-11-30 |
Family
ID=40383701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120870AT HRP20120870T1 (hr) | 2007-11-02 | 2012-10-29 | Protutijela protiv hepcidina i njihova upotreba |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US7820163B2 (hr) |
| EP (2) | EP2209806B1 (hr) |
| JP (1) | JP5469076B2 (hr) |
| KR (2) | KR20120107145A (hr) |
| CN (1) | CN103492414B (hr) |
| AR (1) | AR069062A1 (hr) |
| AU (1) | AU2008318850B2 (hr) |
| BR (1) | BRPI0819211A2 (hr) |
| CA (1) | CA2704527C (hr) |
| CL (2) | CL2008003190A1 (hr) |
| CO (1) | CO6231037A2 (hr) |
| CR (1) | CR11414A (hr) |
| CY (1) | CY1113630T1 (hr) |
| DK (1) | DK2209806T3 (hr) |
| DO (2) | DOP2010000123A (hr) |
| EA (1) | EA023406B1 (hr) |
| ES (1) | ES2392123T3 (hr) |
| HK (1) | HK1142341A1 (hr) |
| HR (1) | HRP20120870T1 (hr) |
| IL (1) | IL205355A (hr) |
| JO (1) | JO2828B1 (hr) |
| MA (1) | MA31886B1 (hr) |
| MX (1) | MX2010004841A (hr) |
| MY (1) | MY155708A (hr) |
| NZ (2) | NZ584997A (hr) |
| PE (1) | PE20091261A1 (hr) |
| PL (1) | PL2209806T3 (hr) |
| PT (1) | PT2209806E (hr) |
| RS (1) | RS52592B (hr) |
| SI (1) | SI2209806T1 (hr) |
| TN (1) | TN2010000201A1 (hr) |
| TW (1) | TWI409276B (hr) |
| UA (1) | UA98983C2 (hr) |
| WO (1) | WO2009058797A1 (hr) |
| ZA (1) | ZA201003025B (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110053268A1 (en) * | 2006-10-17 | 2011-03-03 | Naohisa Tomosugi | Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator |
| PE20090722A1 (es) | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| WO2008146903A1 (ja) * | 2007-05-31 | 2008-12-04 | Naohisa Tomosugi | 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法 |
| TWI409276B (zh) | 2007-11-02 | 2013-09-21 | Lilly Co Eli | 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途 |
| JP2011519279A (ja) * | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| US8609817B2 (en) * | 2008-08-06 | 2013-12-17 | Eli Lilly And Company | Anti-hepcidin-25 selective antibodies and uses thereof |
| DE102009034150A1 (de) | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
| AR077892A1 (es) | 2009-08-20 | 2011-09-28 | Vifor Int Ag | Quinolinas antagonistas de la hepcidina |
| AR077958A1 (es) | 2009-08-27 | 2011-10-05 | Vifor Int Ag | Quinoxalinonas antagonistas de la hepcidina |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| AR078340A1 (es) | 2009-09-07 | 2011-11-02 | Vifor Int Ag | Antagonistas de la etanodiamina-hepcidina |
| WO2011029832A1 (de) | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
| WO2011071368A1 (en) | 2009-12-11 | 2011-06-16 | Umc St. Radboud | Method for measuring hepcidin |
| KR20180088745A (ko) | 2010-08-16 | 2018-08-06 | 피어이스 파마슈티컬즈 게엠베하 | 헵시딘 결합 단백질 |
| US20120214803A1 (en) | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| US9610356B2 (en) | 2011-12-12 | 2017-04-04 | Pieris Pharmaceutical GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| BR112015022123B1 (pt) | 2013-03-15 | 2022-08-09 | Intrinsic Lifesciences, Llc | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| CN104945497B (zh) * | 2014-11-21 | 2018-04-03 | 南京国龙生物科技有限公司 | 一种新型抗菌肽Hep‑W及其制备方法和应用 |
| WO2016137950A1 (en) | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-tau antibodies |
| EP3268027B1 (en) | 2015-03-13 | 2022-11-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Hepcidin antagonists for use in the treatment of inflammation |
| TWI789343B (zh) | 2016-02-01 | 2023-01-11 | 丹麥商碩騰丹麥有限公司 | 微流體分析系統、執行分析的微流體匣及方法 |
| WO2018234538A1 (en) | 2017-06-23 | 2018-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM |
| ES2759622T3 (es) | 2017-10-02 | 2020-05-11 | Certest Biotec S L | Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter |
| CN117903311A (zh) * | 2024-03-20 | 2024-04-19 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3774300A (en) | 1999-06-02 | 2000-12-18 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6262247B1 (en) | 1999-08-30 | 2001-07-17 | Incyte Genomics, Inc. | Polycyclic aromatic hydrocarbon induced molecules |
| JP4944360B2 (ja) | 2001-05-25 | 2012-05-30 | アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） | 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 |
| CN1173737C (zh) | 2002-10-21 | 2004-11-03 | 钱忠明 | Hepcidin(海魄喜定)在制药中的应用 |
| US8017737B2 (en) | 2002-11-19 | 2011-09-13 | Hasan Kulaksiz | Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor |
| US7411048B2 (en) | 2002-11-19 | 2008-08-12 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids |
| WO2004058044A2 (en) | 2002-11-19 | 2004-07-15 | Drg International, Inc. | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor |
| CA2537668A1 (en) | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
| US7723063B2 (en) * | 2004-04-28 | 2010-05-25 | Intrinsic Lifesciences | Methods for measuring levels of bioactive human hepcidin |
| US20090202986A1 (en) | 2004-10-22 | 2009-08-13 | Huse William D | Methods of optimizing antibody variable region binding affinity |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US7510842B2 (en) | 2005-03-11 | 2009-03-31 | Vermilllion, Inc. | Biomarker for ovarian and endometrial cancer: hepcidin |
| PE20090722A1 (es) | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| CN101903044A (zh) | 2007-10-02 | 2010-12-01 | 国家健康与医学研究院 | 对人铁调素具有特异性的抗原结合蛋白 |
| TWI409276B (zh) * | 2007-11-02 | 2013-09-21 | Lilly Co Eli | 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途 |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| US8609817B2 (en) * | 2008-08-06 | 2013-12-17 | Eli Lilly And Company | Anti-hepcidin-25 selective antibodies and uses thereof |
-
2008
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Application Discontinuation
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active IP Right Cessation
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
- 2008-10-29 EP EP08844586A patent/EP2209806B1/en active Active
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/en active Active
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 RS RS20120466A patent/RS52592B/en unknown
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/en active Application Filing
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 CA CA2704527A patent/CA2704527C/en not_active Expired - Fee Related
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
-
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
- 2010-09-15 HK HK10108774.3A patent/HK1142341A1/xx not_active IP Right Cessation
-
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
-
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120870T1 (hr) | Protutijela protiv hepcidina i njihova upotreba | |
| HRP20231569T1 (hr) | Nova protutijela protiv il 13 i njihova upotreba | |
| AU2009279865B2 (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| HRP20191500T1 (hr) | Protutijela protiv cd47 i postupci njihove upotrebe | |
| KR102551444B1 (ko) | 표적 간섭이 억제된 항-약물 항체 분석 | |
| JP2011530514A5 (hr) | ||
| KR102346566B1 (ko) | 섬유성 질환의 치료 방법 | |
| KR102682192B1 (ko) | 메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도 | |
| RU2015104579A (ru) | Диагностические анализы и наборы для детекции фолатного рецептора 1 | |
| RU2019126220A (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
| RU2014146707A (ru) | Антитела против тофацитиниба и их применение для лекарственного мониторинга | |
| RU2739607C2 (ru) | Специфически очищенные антитела против пресепсина | |
| RU2719642C2 (ru) | Способ определения антител к лекарствам в отношении человеческих или гуманизированных лекарственных антител с подавленной эффекторной функцией | |
| CN109313201B (zh) | 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体 | |
| EP3740503A1 (en) | Compounds and methods targeting interleukin-19 | |
| KR102007161B1 (ko) | 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체 | |
| US20220357341A1 (en) | Compositions and methods for an il-17 target engagement assay with small molecule modulators | |
| US20240043508A1 (en) | Antibody binding specifically to sars-cov-2 s protein or antigen-binding fragment thereof, bispecific antibody, and uses thereof | |
| Saiki et al. | Differences in TSH receptor binding and thyroid-stimulating properties between TSH and Graves' IgG. Slowly-acting TSH receptor antibody moieties in Graves' sera affect assay data | |
| KR20230017308A (ko) | 샘플에서 항체의 유리 항원 측정 방법 | |
| JPWO2020158857A1 (ja) | 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット | |
| KR20230083068A (ko) | 인간 코로나바이러스 oc43 n 단백질 특이적인 항체 및 그 응용 | |
| CN114945593A (zh) | 抗IL-1β抗体 | |
| TH126225B (th) | แอนติ-เฮปซิดิน แอนติบอดี และการใช้ของแอนติบอดีนั้น |